114: The Relaxback UK Show with Mike Dilke - Episode 114114: The Relaxback UK Show with Mike Dilke - Episode 114
UK Health Radio Podcast
Mike Dilke and Nick Burgin discuss a new drug that slows Alzheimer's progression by dissolving brain plaques, covering its development and approval challenges.
35:52•1 Apr 2025
Breaking Down Barriers in Alzheimer's Treatment
Episode Overview
- New drug slows Alzheimer's progression by dissolving brain plaques.
- Development process took over 20 years and billions of dollars.
- Clinical trial involved 1,800 patients in Phase 3.
- NICE approval is pending for NHS availability.
- Potential side effects include brain swelling and small hemorrhages.
“It's the first innovation in many years; lots of companies have failed in clinical trials to find a drug that modifies this terrible disease”
Ever wondered about the latest advancements in Alzheimer's treatment? In this episode of The Relaxback UK Show, Mike Dilke chats with Nick Burgin, President of Assay Europe, about a groundbreaking drug designed to slow the progression of Alzheimer's disease. Nick provides an in-depth look at how the drug works by dissolving plaques in the brain, which are believed to cause cognitive decline. The discussion covers the extensive and costly development process, from initial research to clinical trials involving 1,800 patients.
Nick also highlights the challenges faced in getting the drug approved for use on the NHS, including the rigorous criteria set by NICE (National Institute for Health and Care Excellence). This episode is packed with valuable information for anyone interested in the latest medical advancements and the future of Alzheimer's treatment. Tune in to learn more about this innovative drug and its potential impact on patients' lives.
Do you want to link to this podcast?
Get the buttons here!
More From This Show
The latest episodes from the same podcast.
Related Episodes
Similar episodes from other shows in the catalogue.